Low Dose IL2 Immunotherapy in AD

Inclusion Criteria: Diagnosis of probable Alzheimer disease according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria13. Male or female age 60 to 86 years Clinical dementia rating scale of 1 Total bilirubin less than or equal to 1.5mg/dL Alanine aminotransferase level (ALT) less than or equal to five times normal, albumin greater than or equal to 3.0gm/dL Serum creatinine less than 1.5 mg/dL English language speaking A family member or caretaker who is expected to be consistently available, administer study drug and attend study visits throughout the study. Exclusion Criteria: Serious, active bacterial, fungal or viral infection Severe pulmonary dysfunction. FEV1 and FVC less than 40% of predicted (or 3 SD below normal) at baseline, If a pulmonary function test is clinically indicated. Hx of intubation for >72 hours. Severe cardiac dysfunction defined as left ventricular ejection fraction <40% if an echocardiogram is medically indicated to clarify ongoing symptoms or EKG findings.; a history of non-controlled cardiac arrhythmias; history of cardiac tamponade; Unstable angina or MI in the last 3 months Hypersensitivity or allergy to IL-2 Bowel ischemia/perforation, GI bleeding requiring surgery Resistant seizures, history of coma or toxic psychosis lasting >48 hours Patients with White Blood Count (WBC) <4,000/mm3; platelets <100,000/mm3; hematocrit (HCT) <30%.